普伐他汀降低低密度脂蛋白胆固醇对有冠心病风险的轻度高胆固醇血症患者的血小板活化无影响。
Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease.
作者信息
Barrow S E, Stratton P D, Benjamin N, Brassfield T, Ritter J M
机构信息
Department of Clinical Pharmacology, United Medical School, Guy's Hospitals, London Bridge.
出版信息
Br J Clin Pharmacol. 1991 Jul;32(1):127-9. doi: 10.1111/j.1365-2125.1991.tb05625.x.
Abstract
The effect of pravastatin on low density lipoprotein (LDL) cholesterol and platelet activation was studied in 16 patients with mild hypercholesterolaemia who had two or more additional cardiovascular risk factors. Patients were treated with either pravastatin (20-40 mg day-1) or placebo for 1 year. Plasma LDL and urinary excretion of 2,3-dinor-thromboxane B2 (an index of platelet activation in vivo) were determined at 0, 3, 6 and 12 months. There was a significant reduction in LDL at 6 and 12 months (2P less than 0.05) but this was not associated with any significant change in thromboxane metabolite excretion.
摘要
对16例患有轻度高胆固醇血症且有两种或更多其他心血管危险因素的患者，研究了普伐他汀对低密度脂蛋白（LDL）胆固醇和血小板活化的影响。患者接受普伐他汀（20 - 40毫克/天）或安慰剂治疗1年。在0、3、6和12个月时测定血浆LDL以及2,3 - 二去甲血栓素B2的尿排泄量（体内血小板活化的指标）。在6个月和12个月时LDL有显著降低（P小于0.05），但这与血栓素代谢产物排泄的任何显著变化均无关联。
相似文献
1
Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease.普伐他汀降低低密度脂蛋白胆固醇对有冠心病风险的轻度高胆固醇血症患者的血小板活化无影响。
Br J Clin Pharmacol. 1991 Jul;32(1):127-9. doi: 10.1111/j.1365-2125.1991.tb05625.x.
2
Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study.原发性高胆固醇血症患者每日一次服用普伐他汀：一项剂量反应研究。
Clin Cardiol. 1991 Feb;14(2):146-51. doi: 10.1002/clc.4960140211.
3
Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.HMG-CoA还原酶抑制剂普伐他汀（CS-514）对高胆固醇血症患者的剂量依赖性降血脂作用。一项双盲试验。
Atherosclerosis. 1988 Aug;72(2-3):205-11. doi: 10.1016/0021-9150(88)90082-2.
4
Pravastatin--ocular side effects after a two year follow-up?普伐他汀——两年随访后的眼部副作用？
Lens Eye Toxic Res. 1990;7(3-4):311-8.
5
Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins.普伐他汀治疗原发性中度高胆固醇血症：含载脂蛋白B脂蛋白代谢的变化
J Intern Med. 1990 Feb;227(2):81-94. doi: 10.1111/j.1365-2796.1990.tb00124.x.
6
Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I.普伐他汀与吉非贝齐治疗原发性高胆固醇血症的疗效比较。意大利多中心普伐他汀研究I。
Arch Intern Med. 1991 Jan;151(1):146-52.
7
[Evaluation of the efficacy and safety of pravastatin in primary hypercholesterolemia].
Boll Chim Farm. 1990 Jun;129(6):10S-15S.
8
Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels.家族性高胆固醇血症的治疗：普伐他汀或考来烯胺治疗对脂蛋白和载脂蛋白水平影响的对照试验。
J Intern Med. 1990 Sep;228(3):241-7. doi: 10.1111/j.1365-2796.1990.tb00225.x.
9
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.西班牙降胆固醇疗法的成本效益分析。
Am J Cardiovasc Drugs. 2006;6(3):177-88. doi: 10.2165/00129784-200606030-00005.
10
Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.两种不同的HMG-CoA还原酶抑制剂对IIA型高胆固醇血症中血栓素生成的影响。
Biomed Pharmacother. 1996;50(6-7):269-74. doi: 10.1016/0753-3322(96)84824-4.
引用本文的文献
1
Pravastatin for lowering lipids.普伐他汀降血脂。
Cochrane Database Syst Rev. 2023 Sep 18;9(9):CD013673. doi: 10.1002/14651858.CD013673.pub2.
2
Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.普伐他汀。对其在冠心病管理中的药理特性和临床疗效的重新评估。
Drugs. 1997 Feb;53(2):299-336. doi: 10.2165/00003495-199753020-00008.
3
The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia. A double-blind, placebo-controlled, prospective study.洛伐他汀对II型高胆固醇血症患者血小板功能及血小板类花生酸受体的作用。一项双盲、安慰剂对照的前瞻性研究。
Eur J Clin Pharmacol. 1993;45(5):451-7. doi: 10.1007/BF00315517.
4
Influences of lipid-modifying agents on hemostasis.脂质修饰剂对止血的影响。
Cardiovasc Drugs Ther. 1993 Nov;7(5):817-23. doi: 10.1007/BF00878936.
本文引用的文献
1
Platelet function and lipoprotein levels after plasma-exchange in patients with familial hypercholesterolaemia.家族性高胆固醇血症患者血浆置换后的血小板功能和脂蛋白水平
Clin Sci (Lond). 1983 Jun;64(6):637-42. doi: 10.1042/cs0640637.
2
Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.美维诺林和考来替泊可刺激家族性高胆固醇血症杂合子患者血浆中低密度脂蛋白通过受体介导的清除。
Proc Natl Acad Sci U S A. 1983 Jul;80(13):4124-8. doi: 10.1073/pnas.80.13.4124.
3
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study.血清胆固醇、脂蛋白与冠心病风险。弗雷明汉姆研究。
Ann Intern Med. 1971 Jan;74(1):1-12. doi: 10.7326/0003-4819-74-1-1.
4
Clofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia.氯贝丁酯对高β脂蛋白血症患者血小板超敏反应的逆转作用。
Circulation. 1974 Sep;50(3):570-4. doi: 10.1161/01.cir.50.3.570.
5
6
Paired analysis of urinary thromboxane B2 metabolites in humans.人体尿血栓素B2代谢产物的配对分析。
Thromb Res. 1987 Sep 15;47(6):647-56. doi: 10.1016/0049-3848(87)90103-4.
7
Platelet activation by plasma lipoproteins.血浆脂蛋白介导的血小板活化。
Prog Cardiovasc Dis. 1987 Jul-Aug;30(1):61-72. doi: 10.1016/0033-0620(87)90011-9.
8
Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes.吸烟的健康个体血小板和血管功能慢性异常的生化证据。
Circulation. 1987 Jul;76(1):6-14. doi: 10.1161/01.cir.76.1.6.
9
Measurement of renal and non-renal eicosanoid synthesis.肾脏和非肾脏类花生酸合成的测量。
Am J Med. 1986 Aug 25;81(2B):23-9. doi: 10.1016/0002-9343(86)90905-8.
10
Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients.辛伐他汀对IIa型高胆固醇血症患者血小板聚集及血栓素B2合成的影响。
Atherosclerosis. 1989 Sep;79(1):79-83. doi: 10.1016/0021-9150(89)90036-1.
Zotero 插件